



**CARBAPENEM RESISTANCE-DETERMINING GENES AMONG MULTI-DRUG  
RESISTANT BACTERIAL ISOLATED FROM CLINICAL SAMPLES IN BASRAH  
GOVERNORATE**

Ismael Jmia Abas and Maytham A. Al-Hamdani\*

Department of Biology- College of Education for Pure Sciences-Basrah University, Basrah –Iraq.

\*Corresponding Author: Maytham A. Al-Hamdani

Department of Biology- College of Education for Pure Sciences-Basrah University, Basrah –Iraq.

Article Received on 30/03/2017

Article Revised on 20/04/2017

Article Accepted on 10/05/2017

### ABSTRACT

Increasing resistance to carbapenems, may significantly reduce the choice of effective antibiotics. This study was conducted to determine the occurrence of carbapenemase producing bacteria isolates obtained from Basrah hospitals. Isolates were identified. And Carbapenem susceptibility was assayed by using VITEK 2 system. Phenotypic detection of carbapenemase was performed using four method Combined disc test, modified Hodg tests, RAPIDEC CARBA NP test, ChromID Carba media. Then isolates were subjected to monoplex PCR targeting blaNDM-1 and OXA-48 genes. 61(20.74%) Carbapenem Resist gram negative Bacteria isolates were recovered from clinical samples. 61 (100%) of isolate was found to be imipenem resistant. 31 (70.45%) of isolates give positive result to Combined disc test from 44 isolates which give positive rustle in PCR method whereas 35(79.54%) isolates showed positive results with modified Hodg test, 41(93.18%) of isolates give positive result to ChromIDCarba media, while 44(97.72%) of isolates give positive result to RAPIDEC CARBA NP test .PCR experiments showed 29 (47.54%) isolates were harbored blaNDM-1gene and 28(45.90%) isolates were harbored OXA-48gene.

### INTRODUCTION

Carbapenemases are a group of enzymes that are able to hydrolyze carbapenems even at low level (DeAndrade *et al.*, 2010; Rahmati *et al.*, 2013). There are two main molecular families of carbapenemases: serine carbapenemases, which is based on presence of serine in their active site and metallo-carbapenemases, which are a subgroup of metallo-  $\beta$ -lactamases (MBLs) having at least one zinc atom at their active site (Bahar *et al.*, 2010) Based on amino acid homology carbapenemases have been identified in each of the three Ambler molecular classification, however those of class A, B, and D have major epidemiological impact, Class A This group contains serine at their active site and are capable of hydrolyzing all  $\beta$ -lactams, such as aztreonam. In this group of carbapenemases, IMI, Sme, SFC-1 and NmcA, enzymes are mostly chromosomally encoded, (Bedenic *et al.*, 2014) Class B carbapenemases are also known as metallo-  $\beta$ -lactamase since they contain two zinc ions in their active site Class B MBLs are mostly VIM and IMP types, but the recently emerged NDM-type (New Delhi metallo-  $\beta$ -lactamases) is becoming the most threatening carbapenemase (Levy Hara *et al.*, 2013) Class D which named OXAs for oxacillinases, have more than 440 known variants with 232 of them showing carbapenemase activity and majority of them are OXA-48 (Djahmi *et al.*, 2014).

### METHOD AND MATERIAL

#### Isolation and Identification of Isolates

One thousand and four hundred twenty two (1423) isolates were recovered from different clinical samples in six Hospitals in Basrah \Iraq during one year period starting from February, 2015 to February, 2016 Isolates were recovered from clinical samples after culturing on MacConkey agar and incubated for overnight at 37°C. For 24-48 h, and then identified by using of VITEK 2 Automated system using (GN) cards.

#### Antibiotic susceptibility testing

VITEK 2 system using (AST- GN327) was used, and the MIC values for these isolates were obtained The susceptibility of the isolates was determined against 15 antibiotics included: Piperacillin(PRL), Piperacillin/Tazobactam(TPZTZP), Ceftazidime(CAZ)Cefepime, (FEP)Aztreonam(ATM), imipenem(IMP), Meropenem(MEM)0, Amikacin(AK)Gentamicin(CN), Netilmicin(NTE), Tobramycin(TOP), Ciprofloxacin(CIP), Levofloxa(LVE), tetracycline(TE)Trimethoprim/Sulfamethoxazole remaining(SXT)

#### Combined disc test

Screening for MBLs was performed using disks containing 1900  $\mu$ g of EDTA plus 10  $\mu$ g of imipenem

disk were placed on the inoculated plates containing Muller Hinton agar. An increase of  $\geq 17$  mm in zone diameter in the presence 1900  $\mu\text{g}$  of EDTA compared to imipenem alone indicated the presence of an MBL (Lee *et al.*, 2003).

#### Modified Hodge test (MHT)

This test was carried out to detect carbapenemase using imipenem or meropenem as described by Clinical and Laboratory Standards Institute (2014).

#### RAPIDEC CARBA NP test

Carba NP is a phenotypic test that detects carbapenemases by measuring the in vitro hydrolysis of imipenem by a bacterial extract. Imipenem hydrolysis changes the pH and produces a resultant color change of a pH indicator.

#### Chrom ID Carba media

The used ChromID Carba medium for investigation of the producing of Carbapenemase enzymes.

#### PCR amplification

DNA was extracted from the isolates by using plasmid extraction mini kit according to the manufacture instructions (Bioneer Company, Korea). To amplify the genes encoding carbapenemases, a monoplex-PCR was run using the primers of NDM-1 (621bp: F/'5-GGTTTGCGATCTGGTTTTTC -3'and R/'5-CGGAATGGCTCATCACGATC -3') were designed in this study and OXA-48 gene (238 bp: F/'5GCTTGATCGCCCTCG ATT-3' and R/'5-GATTTGCTCCGTGGCCGAAA -3') Amplification was

performed in a 20 $\mu\text{l}$  volume as recommended by Promega Master mix instruction. PCR amplifications were carried out on a thermal cycler (Claver,England). The cycling conditions for amplification were as follows: for *bla*NDM-1 gene, initial Denaturation at 94 °C for 3 min, followed by 35 cycles of 94°C for 45s, 48°C for 35 sec and 72 °C for 35 sec with final incubation at 72°C for 7 min, and for OXA-48 initial Denaturation at 94°C for 3 min, followed by 35 cycles of 94 °C for 45s, 57°C for 35 sec and 72°C for 35 sec with final incubation at 72°C for 7 min. Amplified products were detected by agarose gel electrophoresis in 1% Tris-borate-EDTA (TBE) agarose (Promega, USA) and staining with ethidium bromide. The electrophoresis result was detected by using gel documentation system (Claver, England).

#### DNA Sequencing

DNA sequencing method was performed for genotyping and phylogenetic analysis study of bacteria isolates. The sequencing of the PCR product 621bp, and 238bp, for NDM-1, and OXA-48, gene respectively, the PCR product was purified by using specialized Kit.

#### RESULTS

One thousand and four hundred twenty two (1423) isolates were recovered from different clinical samples in six Hospitals in Basrah \Iraq during one year period starting from February, 2015 to February, 2016. Two hundred and ninety four Isolates were gram negative (294) and only sixty one (61) isolates identified as Carbapenem resistant gram negative. Which resist at less of one of antibiotic (Meropenem or Imipenem) table 1.

**Table: 1. Total number of isolates.**

Total	Gram Negative Bacteria	Carbapenem Resist Bacteria.
1423	294	61
100%	20.66%	20.74%

#### Distribution of Carbapenem Resistant Gram Negative Bacteria

Out of the 61 isolates that were found to be resistant to carbapenem,18 isolates were *Escherichia coli* (29.50%),14 *Klebsiella pneumoniae* (22.95%), seven

*Pseudomonas aeruginosa* (11.47%), six isolates(9.83%) for both *Proteus mirabilis*, *Acinetobacter baumannii* , *Burkholderia cepacia* and one isolate (1.63%) for both, *Citrobacter frundill*, *Enterobacter cloacae* , *Serratia fonticola* , *Serratia marcescens* table 2.

Table: 2. Distribution of Carbapenem Resistant Gram Negative Bacteria

Total CRGNB	<i>E.coli</i>	<i>K. pneumoniae</i>	<i>P. aeruginosa</i>	<i>Proteus mirabilis</i>	<i>Acinetobacter baumannii</i>	<i>Burkholderia cepacia</i>	<i>Citrobacter frundill</i>	<i>Enterobacter cloacae</i>	<i>Serratia fonticola</i>	<i>Serratia marcescens</i>
61	18	14	7	6	6	6	1	1	1	1
100%	29.50%	22.95%	11.47%	9.83%	9.83%	9.83%	1.63%	1.63%	1.63%	1.63%

**Source of the Clinical Isolates**

Sixty one clinical isolates of Carbapenem Resistant Gram Negative Bacteria (CRGNB) were collected from

seven sources; Burn (19) Urine (12), Blood (8), Ear swabs (10), wound (7), tissue (4) sputum (1) table 3.

**Table: 3 Source of the Clinical Isolates**

sources	Burn	Urine	Ear swabs	Blood	wound	tissue	sputum
CRGNB	19	12	10	8	7	4	1
Percent %	31.14%	19.67%	16.39%	13.11%	11.47%	6.55%	1.63%

**Relation between Hospital unite and Carbapenem Resistant Bacteria**

Twenty four 24(39.34%) of our isolates Carbapenem Resistant Gram Negative Bacteria were collected from Burn unite, nine (14.75%) from Urology unite, nine

(14.75%) from ENT unite, eight (13.11%) Surgery unite, four (6.55%) from Diabetic foot unite, three (4.91%) Medicine unite, two (3.27%) from ICU, and one (1.63) from both O.P and Chest unite table 4.

**Table: 4 Relation between Hospital unite and Carbapenem Resistant Bacteria**

Hospital unite	Burn unite	Urology unite	ENT unite	Surgery unite	Diabetic foot unite	Medicine unite	ICU	Chest unite	O.P
CRGNB	24	9	9	8	4	3	2	1	1
Percent %	39.34%	14.75%	14.75%	13.11%	6.55%	4.91%	3.27%	1.63%	1.63%

**Antibiotic susceptibility testing**


VITEK 2 system using (AST- GN327) was used, and the MIC values for these isolates were obtained the susceptibility of the isolates was determined against 15 antibiotics included: Piperacillin(PRL), Piperacillin/Tazobactam(TPZ-TZP), Ceftazidime(CAZ) Cefepime, (FEP) Aztreonam(ATM), imipenem(IMP), Meropenem(MEM), Amikacin(AK) Gentamicin(CN), Netilmicin(NTE), Tobramycin(TOP), Ciprofloxacin(CIP), Levofloxa(LVE), Tetracycline (TE) Trimethoprim/Sulfamethoxazole remaining (SXT).

Extended-spectrum cephalosporins group Ceftazidime (CAZ) Cefepime, (FEP) were (75.40% and 78.68%) respectively Aztreonam (ATM) are antibiotic from Monobactams group which show 75.40% resistant in our isolates, Aminoglycosides antibiotic group, Amikacin (AK), Gentamicin (CN), Netilmicin (NTE), Tobramycin (TOP), show resistant (67.21%, 81.96%, 85.24%, 88.52%) respectively Ciprofloxacin (CIP), Levofloxacin (LVE), recorded resistance; 85.24% and 88.52%, in this study, resistant rate to Tigecycline about (73.77%). and to Trimethoprim/Sulfamethoxazole remaining (SXT) about (70.49%) table.5 figure.1.

All isolates were resistant 61(100%) to Impinem and 46(75.40%) were resistant to Meropenem the resistant to

**Table 3 Antibiotic resistance rates of most commonly isolated carbapenem-resistant isolates in our study**

Antibiotic	No.of Resistant	No.of Intermediate	No.of Sensitive
PR1	51(83.60%)	0(0%)	10(16.39)
TPZ.TZP	48(78.68%)	2(3.27%)	11(18.03%)
CAZ	46(75.40%)	2(3.27%)	13(21.31%)
FEP	48(78.68%)	7(11.45%)	6(9.83%)
ATM	46(75.40%)	3(4.91)	12(19.67%)-
IPM	61(100%)	0(0%)	0(0%)
MEM	46(75.40%)	4(6.55%)	11(18.03%)
AK	41(67.21%)	4(6.55%)	16(26.22%)
CN	50(81.96%)	3(4.91%)	8(13.11%)
NET	52(85.24%)	3(4.91%)	6(9.83%)
TOB	54(88.52% )	1(1.63%)	6(9.83%)
CIP	52(85.24% )	5(8.19%)	4(6.55%)
LEV	54(88.52% )	2(3.27%)	7(11.47%)
TE	45(73.77%)	5(8.19%)	3(4.91%)
SXT	43(70.49%)	0(0%)	18(29.50%)



**Figure.1. Antibiotic percentage resistance rates of most commonly isolated carbapenem-resistant isolates in our study**

#### Phenotypic detection of carbapenem production

Thirty one (70.45%) of isolates give positive result to Combined disc test from 44 isolates which give positive result in PCR method whereas 35 (79.54%) isolates showed positive results with modified Hodg test,

41 (93.18%) of isolates give positive result to ChromIDCarba media, while 44 (97.72%) of isolates give positive result to RAPIDEC CARBA NP test table 4.

**Table 4. Phenotypic detection of carbapenem production**

Combined-Diffusion -Disc Test (CDDT)	Modified Hodge test (clover leaf test) (MHT).	RAPIDEC CARBA NP test	ChromID Carba media	PCR
31	35	43	41	44
44	44	44	44	44
70.45%	79.54%	97.72%	93.18%	100%

#### Genotypic detection of carbapenem genes

PCR amplification of NDM -1 gene show that 29 (47.54%) of isolate harbor NDM-1 gene alone or co-produce with OXA-48 gene, the high present of NDM-1 gene found in *E.coli* 14 (22.95%) flow by *K.pneumonia* 8 (13.11%), *Pseudomonas aeruginosa* 4 (6.55%) *Acinetobacter baumannii* 3 (4.91%). OXA-48 gene was

present in 28 (45.90%) of isolates .alone or co-produce with NDM-1, The high present of the gene was founded in *K.pneumonia* 13 (21.31), *E.coli* 6 (9.83%) *Acinetobacter baumannii* 3 (4.91%), *proteus mirabilis* 2 (3.27%), *Burkholderia cepacia2* (3.27%), *Enterobacter cloacae* 1 (1.63%), *Serratia marcescens* 1 (1.63%). Table 5 Figure (2,3).

**Table: 5. Present of genes in different isolates**

Bacteria	NDM-1 gene	OXA-48 gene
Escherichia coli	14	6
Klebsiella pneumoniae	8	13
Proteus mirabilis	0	2
Pseudomonas aeruginosa	4	0
Acinetobacter baumannii	3	3
Burkholderia cepacia	0	2
Citrobacter frundill	0	0
Enterobacter cloacae	0	1
Serratia marcescens	0	1
Serratia fonticola	0	0
Total	29 (47.54%)	28 (45.90%)




Figure 2. Agarose gel electrophoresis (1.5% agarose,70 volt for 1-2 hrs) for blaNDM-1 gene product (amplified size 620 bp) isolates show positive results with blaNDM-1 gene.




Figure 3. Agarose gel electrophoresis (1.5% agarose,70 volt for 1-2 hrs) for OXA-48 gene product (amplified size 238 bp) isolates show positive results with OXA-48 gene

#### Sequence analysis of NDM-1 in *E. coli*

BlaNDM-1 specific amplicons were sequenced only three isolates (*E.coli* 1, *E.coli* 11 *E.coli* 15) which have different pattern of antibiotic resistant. The DNA sequence identity was confirmed using BLASTN

analysis. These three DNA sequences together with four similar sequences, retrieved from NCBI Gen Bank database under accession numbers (KR872634.1, KR872624.1, NC023908.1, JN255860) figure.





Figure 4. Phylogenetic analysis based on blaNDM-1 gene sequences obtained from the three *E. coli* isolates in this study and four sequences retrieved from GenBank database (NCBI).

**Sequence analysis of NDM-1 in *K.pneumonia***

NDM-1 gene were sequenced two isolates (*K.pneumonia*.8 *K.pneumonia*14) which have different pattern of antibiotic resistant. The DNA sequence identity was confirmed using BLASTN analysis. These

two DNA sequences together with five similar sequences, retrieved from NCBI Gen Bank database under accession numbers (LC154933.1, LC154959.1, LT615329.1, KX218441.1, KX987870.1).




**Figure 5. Phylogenetic analysis based on blaNDM-1 gene sequences obtained from the two *K.pneumonia* isolates in this study and five sequences retrieved from GenBank database (NCBI).**

**Sequence analysis of OXA-48 in *E. coli***

The DNA sequence of OXA-48 gene in *E. coli* identity was confirmed using BLASTN analysis. The three DNA sequences together with four similar sequences, retrieved

from NCBI Gen Bank database under accession numbers (KP998754.1, KM575914.1, NG\_049724.1, NG\_049462.1, KT175900.1).




**Figure 6. Phylogenetic analysis based on OXA-48 gene sequences obtained from the three *E. coli* isolates in this study and seven sequences retrieved from GenBank database (NCBI).**

**Sequence analysis of OXA-48 in *K.pneumonia***

The DNA sequence of OXA-48 gene in *K.pneumonia* identity was confirmed using BLASTN analysis. The three DNA sequences together with seven similar

sequences, retrieved from NCBI Gen Bank database under accession numbers (KY094764.1, KY094766.1, KY094765.1, KM575914.1, KU821690.1, KU821688.1, KU821691.1).



**Figure 7. Phylogenetic analysis based on OXA-48 gene sequences obtained from the three *K.pneumonia* isolates in this study and seven sequences retrieved from GenBank database (NCBI).**

## DISCUSSION

Carbapenem resistance in Gram-negative bacteria is increasingly encountered in healthcare-associated infections in Iraq because increasing resistance in Gram-negative bacteria has been associated with heavy antibiotic use, including carbapenems. In Iraq various studies have found different rates of carbapenem resistance. In April - October 2011, a study was conducted in Sulaimani City. In this study overall Meropenem resistance was 22% from Gram Negative Bacteria (Anoar *et al.*, 2014). In 2008 a study was conducted in Baghdad. In this study overall Imipenem resistance was 20% *Pseudomonas aeruginosa* (AL- Marjani *et al.*, 2010). In the present study, the overall resistance to carbapenems was 20%, which is in comparison with the study of Manoharan *et al.* whose reported 17% resistance to carbapenems in Enterobacteriaceae (Manoharan *et al.*, 2011) 15]. Also, (Dutta *et al.*, 2012; Wattal *et al.*, 2010; and Gupta *et al.*, 2006) showed 7.87%, 13-57% and 17-22% resistance to carbapenems respectively.

In our study high isolates were *E. coli* and *Klebsiella pneumoniae* this result is in accordance with study by Chakravorty *et al.* in India which found that the most common Gram negative bacilli responsible for carbapenem resistance was *Escherichia coli* Chakravorty *et al.* (2016).

According to the sources of carbapenem resistant high rate of isolates found in burns (31%) Burns provide a suitable site for bacterial multiplication and are more persistent richer sources of infection than other sources, mainly because of the larger area involved and longer duration of patient stay in the hospital (Agnihotri *et al.*, 2004).

In our study the high ratio of Carbapenem Resistant Bacteria isolate from burns unit (39%) which is alone unit in basrah and there are overcrowding in it, these led to increasing resistant bacteria to antibiotic because, Overcrowding in burns units is an important cause of cross infection which necessitates a regular monitoring of bacterial species and their antibiotic susceptibilities

because significant shifts in these data may be correlated with changes in clinical management with respect to drug choice for therapy (Gupta *et al.*, 1993).

VITEK 2 system using (AST- GN327) was used, and the MIC values for these isolates were obtained. We use this system to determine the MIC values, because there are many studies report the benefit of use it. Shah *et al.* conclude that Vitek 2 compact is an automated system and gives more accurate results than double disk diffusion method. (Shah *et al.*, 2016) Bae IK, *et al.* The VITEK AST- card showed high sensitivity for the detection of carbapenemases in Enterobacteriaceae strains. (Bae IK, *et al.*, 2015).

All isolates were resistant 61(100%) to Imipenem and 46(75.40%) were resistant to Meropenem. Our study shows high resistance to carbapenem antibiotics compared with study in Erbil which use Vitek 2 compact system, show that in among Gram negative bacteria the most effective antibiotics that have low percentage of resistance were Meropenem (0%) and for Imipenem was 5 (6.8%) (Ahmad and Fattma, 2014) and agreement with results in study on *Pseudomonas aeruginosa* isolated from Public and Private Hospitals in Baghdad which show from six isolates four 66.66% are resistant to Meropenem and all of them (100%) are resistant to Imipenem (Al-Charrakh *et al.*, 2014). The isolates in our study show 83.60% and 78.68% resisted to penicillins+beta-lactamase inhibitors antibiotic group Piperacillin (PRL) and Piperacillin/tazobactam (TPZ-TZP) these results agreement with results (Hussein *et al.*, 2013; Al-Charrakh *et al.*, 2014).

The resistant to Extended-spectrum cephalosporins group Ceftazidime (CAZ) Cefepime, (FEP) were (75.40% and 78.68%) respectively, in other local studies, Alsehlawi, *et al.* (2014) and AL-kadhmi, (2015) reported that resistance rate to ceftazidime, cefotaxime and cefepime were (100%). A report by Chaiwarith, *et al.*, (2005) documented that susceptibility to ceftazidim and Cefepime were equal, (70%) in isolates collected from Thailand hospitals. High level of resistance to third



generation cephalosporins could be attributed to the production of ESBLs, since it mediates resistance to broad spectrum cephalosporins (e.g., ceftazidime, ceftriaxone and cefotaxime) and aztreonam (Shaikh *et al.*, 2015). Aztreonam (ATM) are antibiotic from Monobactams group which show 75.40% resistant in our isolates study which agreement with (McWilliams *et al.*, 2014).

Aminoglycosides antibiotic group, Amikacin (AK), Gentamicin (CN), Netilmicin (NTE), Tobramycin (TOP), show resistant (67.21%, 81.96%, 85.24%, 88.52%) respectively. Results of the present study revealed that amikacin was more effective than other aminoglycosides, gentamicin and Tobramycin. This result was parallel with other studies worldwide, as with Leepethacharat and Oberdorfer (2007) in Thailand and Özdemir, *et al.*, (2011) in Turkey. In another study in Najaf Alsehawi, *et al.* (2014) who found that resistance against aminoglycosides were (58.3%) to amikacin, whereas gentamicin and Tobramycin (83.3%). High efficiency of amikacin may be due to its less vulnerability to bacterial enzymes than other aminoglycosides. amikacin usage has been limited because prolonged use was found to cause kidney damage and injury to the auditory nerves leading to deafness (Goni-Urriza *et al.*, 2000). The reduced use of this class of antibiotics may explain the low resistance levels of the isolates to the antibiotics in this class (Divya, 2014). (gentamicin and Tobramycin resistance is often due to the expression of a variety of modifying enzymes including aminoglycoside modifying enzymes (AME), acetylases, phosphorlyases and adenylases which can impair the effectiveness of antibiotics. Other resistance mechanisms include changes in bacterial membrane permeability and altered ribosomal proteins (Barros *et al.*, 1999).

Ciprofloxacin (CIP), Levofloxacin (LVE), recorded resistance; 85.24% and 88.52%, respectively these antibiotic belongs to Fluoroquinolones antibiotic category. Fluoroquinolones resistance results from mutations in the chromosomally encoded type II topoisomerases, and via the up regulation of efflux pumps, or point-related genes (Drlica and Zhao, 1997; Tran *et al.*, 2005). The plasmid qnr genes play an emerging role in the dissemination of fluoroquinolone resistance (Firoozeh *et al.*, 2014).

We found, in this study, resistant rate to Tigecycline about (73.77%). Tigecycline remains as one of the few therapeutic options for infections due to ESBL-producing isolates (Sader *et al.*, 2013; Kelesidis *et al.*, 2008) therefore, the usage and close monitoring of its resistance are important. (Nigo *et al.*, 2013) Resistance to tetracycline is usually conferred through acquisition of resistance genes associated with mobile genetic elements (Roberts, 2005) the high rate of resistant to Tigecycline in our study agreement with study Taiwan, show 100% resistant to Tigecycline (Chiu *et al.*, 2017).

The resistant rate to Trimethoprim/Sulfamethoxazole remaining (SXT) in our study (70.49%) this result agreement with (Prakash *et al.*, 2009; Pitout and Laupland, 2008).

The high levels of resistance to antibiotics in the present study may be as a result of both intrinsic and acquired mechanisms and Carbapenem resistant bacteria mostly carry genes responsible for resistance to the antibiotics like fluoroquinolones, trimethoprim-sulfamethoxazole and aminoglycosides on same transposon (Bratu *et al.*, 2005). The resistance is widespread and constitutes serious clinical threat (Mathur *et al.*, 2002). In addition, the selection pressure of antibiotics in hospital environment lead to multiple resistance to these drugs. El-Astal, (2005) mentioned that inappropriate and incorrect administration of antimicrobial agents and lack of appropriate infection control strategies may be the possible reasons behind increasing resistant rate of bacteria to common used antimicrobial drugs.

In our study we find 31 (70.45%) of isolates give positive result to combined-disc synergy test (CDT) Different studies which have used the combined-disc synergy test (CDT) MBLs production agreement with our result, in Iraq a study with aim determine the possibility of existence of NDM-1 gene among *P. aeruginosa* isolates collected from Najaf hospitals Alshara *et al.* found 77.8% of research isolates were positive to this test (Alshara *et al.*, 2014), other study in Irbil from 34 gram negative bacteria authors found 23 (67.6%) were positive to this test (Bakir and Fattma, 2015).

Another method to detection of Carbapenemes production among the Carbapenem Resistant isolates was done by Modified Hodge test the presence of a cloverleaf shaped zone of inhibition due to carbapenemase production by the test strain was considered as positive. (Lee *et al.*, 2001; Lee *et al.*, 2003; Yong *et al.*, 2002).

35 (79.54%) of isolates in present study give positive results to MHT. The phenotypic assays, MHT has been suggested as the gold standard technique to detect carbapenemase producing bacteria in the past years (Nordmann *et al.*, 2012). Our results showed that MHT failed to detect nine isolates which were PCR positive for NDM gene or OXA-48. Doyle *et al.*, found that the sensitivity of MHT was 61% (Doyle *et al.*, 2012). MHT is less reliable to detect NDMs, VIMs, and IMPs producing bacteria; however, it may be useful for detecting KPC and OXA-48 producers (Nordmann *et al.*, 2011; Castanheira *et al.*, 2011; Doyle *et al.*, 2012).

Carba NP is a phenotypic test that detects carbapenemases by measuring the *in vitro* hydrolysis of imipenem by a bacterial extract. In our study the RAPIDEC CARBA NP test give high sensitivity (97.72%) of isolates which can produce carbapenemases, Different studies have reported the

Carba NP test sensitivities ranging from 80% -100%, with specificity of 100%. (Nordmann *et al.*, 2012b ; Knox *et al.*, 2014; Vasoo *et al.*, 2013) Our result agreement with García-Fernández *et al.* whom, Showed that RAPIDEC CARBA NP test be fast and cost-effective, with high sensitivity (98% to 100%) and specificity (100%), (García-Fernández *et al.*, 2016).

The current study showed that 41 (93%) isolates gave positive results on ChromIDCarba medium this agreement with result by (Vrioni *et al.*, 2012; Simner *et al.*, 2015).

The increasing reports on NDM-1 producing in gram negative bacteria have addressed a potential threat to global health. The high present of NDM-1 gene found in *E.coli* 14(22.95%) flow by *K.pneumonia* 8(13.11%), *Pseudomonas aeruginosa* 4(6.55%) *Acinetobacter baumannii* 3(4.91%). In Iraq NDM-1 gene was report in *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* (Poireletal2011; AL-Harmoosh and Jarallah, 2014; Anoar *et al.*, 2014; Alshara *et al.*, 2013) Till now there are no published works in Iraq reporting NDM-1 gene in *E.coli* The present study gives an initial insight on the incidence of bla NDM-1 gene in the clinical isolates of *E. coli*.

In present study we found the OXA-48 gene were increase in carbapenem resistance *Klebsiella pneumonia* isolates about (46.42%) Our result agreement with report In Moscow, Russia. During the period of January, 2013 to October, 2014, which found the blaOXA-48-carbapenemase genes were detected in 55.3 % of *K. pneumoniae*, (Fursova *et al.*, 2015).

While were used to construct the phylogenetic tree in order to understand the nearest neighbor of the study sequences. The genetic divergence and homogeneity of the sequences are apparent in the phylogenetic tree Figure 5 these sequences were closely placed in the phylogenetic tree and their genetic similarity with four sequences reported from India.

## CONCLUSION

Our study has shown the spreading of multidrug resistant and carbapenem resistant gram negative isolates among patients with different infections. Hence, it is suggested that, such isolates, which consequently poses an increased threat to hospitalized patients in basrah hospitals and more importantly, avoiding misuse and overuse of antibiotics may reverse the undesired effects of multidrug resistant bacteria.

## REFERENCES

1. Agnihotri N, Gupta V, Joshi RM Aerobic bacterial isolate from burn wound infections and their antibiograms - a five - year study. *Burns*, 2004; 30: 241-243.
2. Ahmad Shilan S. Fattma A. Ali Detection Of Esbl, Ampc And Metallo Beta- Lactamase Mediated

- Resistance In Gram- Negative Bacteria Isolated From Women With Genital Tractinfection *European Scientific Journal.*, 2014; 10(9): 1857-7881.
3. AL- Marjani F Mohammed, Makarim A. Khalil, Zina H. Jazar, Zaid N. Hassen Detection of Multidrug resistant *Pseudomonas aeruginosa* Isolates producing IMP-1 Metallo- $\beta$ -Lactamase in some Baghdad hospitals *Tikrit Journal of Pure Science*, 2010; 15(1): 188-192.
4. Al-Charrakh Alaa H. Salwa J. Al-Awadi, and Ahmed S. Mohammed. Detection of Metallo- $\beta$ -Lactamase Producing *Pseudomonas aeruginosa* Isolated from Public and Private Hospitals in Baghdad, Iraq. *Acta Medica Iranica*, 2014; 54(2): 107-113.
5. AL-Harmoosh, Raad, Abdulabass; and Eman, M. Jarallah. First detection of theblaNDM-1 and bla NDM-2 genes in a clinical isolate s of *Acinetobacterbaumannii* in Hillah hospitals-Iraq. *International Journal of Advanced Resear.*, 2014; 10: 1407-1416.
6. AL-kadhmi, N.A.A. Multidrug Resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Isolated from Patient's wounds. A Report of Higher Diploma. Genetic Engineering and Biotechnology Institute for Postgraduate Studies / University of Baghdad, 2015.
7. Alsehlawi, Z. S.; Alshara, J. M.; Hadi, Z.J. and Almohana, A.M. First report of the blaOxa-23 gene in a clinical isolates of *Acinetobacter baumannii* in Najaf hospitals-Iraq. *Int. J. Recent Sci. Research*, 2014; 5(8): 1407-1411.
8. Alshara, Jamal, Mohammed; Zuhair Sadiq, R. Alsehlaw; Dheyaa, Shnan, A, Aljameel; Zee nash .AlZubb-edy; and Ali, M. Almohana. First report of new delhi metallo-beta-lactamas(ndm-1) producing *Pseudomonas aeruginosa* in Iraq *journal of biology, agriculture and healthcare*, 2014; 4(14): 2224-3208.
9. Anoar Khanda Abdulateef. Fattma Abodi Ali and Sherko Ali Omer. Detection of metallo  $\beta$ -lactamase enzyme in some gram negative bacteria isolated from burn patients in sulaimani city, Iraq. *European Scientific Journal*, 2014; 10(3): 1857-7881.
10. Bae Il Kwon, Hyun-Kyung Kang, In-Ho Jang, Woonhyoung Lee, Keonhan Kim, Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates Using the VITEK AST-N202 Card Infect Chemother, 2015; 47(3): 167-174.
11. Bakir Sevan H. &Fattma A. Ali "Evaluation of Multi-drug Resistance and ESBL, AmpC, Metallo  $\beta$ -Lactamase Production in Gram Negative Bacteria Causing Pharyngotonsillitis *International Journal of Research in Pharmacy and Biosciences*, 2015; 2(I7): 1-10.
12. Barros, J.C.S.; Bozza, M.; Gueiros-Filho, F.J; Bello, A.B.; Lopes, U.G and Pereira, J.A.A. Evidences of gentamicin resistance amplification in *Klebsiella pneumoniae* isolated from faeces of hospitalized newborns. *Mem. Inst. Oswaldo Cruz. Rio de Janeiro*, 1999; 94(6): 795-802.

13. Bahar MA, Jamali S, Samadikuchaksaraei A. Imipenem-resistant *Pseudomonas aeruginosa* strains carry metallo-beta-lactamase gene bla(VIM) in a level I Iranian burn hospital. *Burns*, 2010; 36: 826-30.
14. Bedenic B, Plecko V, Sardelic S, Uzunovic S, Godic Torkar K. Carbapenemases in gram-negative bacteria: laboratory detection and clinical significance. *Biomed Res Int.*, 2014; 841951.
15. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement, M100-S24. CLSI document Wayne, PA: Clinical and Laboratory Standards Institute, 2014.
16. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and *Acinetobacter baumannii* in Mediterranean countries. *Biomed Res Int.*, 2014; 305784.
17. Levy Hara G, Gould I, Endimiani A, Pardo PR, Daikos G, Hsueh PR, et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. *J Chemother*, 2013; 25: 129-140.
18. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. *Journal of Antimicrobial Chemotherapy*, 2005; 56: 128-132.
19. Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N, Jones RN. Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. *Diagn. Microbiol. Infect. Dis.*, 2013; 75: 210-213.
20. Chaiwarith, R.; Mahatthanaphak, S.; Boonchoo, M.; Supparatpinyo, K. and Sirisanthana, T. Pandrug Resistant *Acinetobacter baumannii* at Maharaj Nakorn Chiang Mai Hospital. *J. Infect. Dis. Antimicrob. Agents*, 2005; 22(1): 1-8.
21. Chakravorty Sriparna, Soma Sarkar, Manideepa SenGupta, Anita Nandi Mitra, Sonia Jain, and Arunansu Talukdar. Evaluation Of Various Phenotypic Methods For Detection Of Carbapenemase Production In Carbapenem Resistant Gram Negative Bacteria *European Journal of Biomedical and Pharmaceutical Sciences*, 2016; 3(4): 274-278.
22. Chiu S-K, Chan M-C, Huang L-Y, Lin Y-T, Lin J-C, Lu P-L, et al. Tigecycline resistance among carbapenem-resistant *Klebsiella pneumoniae*: Clinical characteristics and expression levels of efflux pump genes. *PLoS ONE*, 2017; 12(4): 175140.
23. Divya P. S. Molecular Epidemiology of *Escherichia coli* isolates from Environmental, Food and Clinical Sources Thesis submitted to Cochin University of Science and Technology in Partial Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Biotechnology. India, 2014.
24. Doyle D, Peirano G, Lascos C, Lloyd T, Church DL, Pitout JDD. Lab-oratory detection of Enterobacteriaceae that produce carbapenemases. *J Clin Microbiol*, 2012; 50: 3877-80.
25. De Andrade SS, Gales AC, Sader HS; Antimicrobial resistance in Gram-negative bacteria from developing countries. *Antimicrobial resistance in developing countries*: Springer, 2010; 249-66.
26. Drlica, K. and Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol .Mol. Biol. Rev.*, 1997; 61: 377-392.
27. Dutta P, Gupta V, Garg S, Chander J Phenotypic method for differentiation of carbapenemase in Enterobacteriaceae: study from north India. *Indian J Pathol Microbiol*, 2012; 55(3): 357-360.
28. El-Astal, Z. Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. *J. Biomed Biotechnol*, 2005; 3: 238-241.
29. Firoozeh, F.; Zibaei, M. and Soleimani-As, Y. Detection of plasmid mediated qnr genes among the quinolone-resistant *Escherichia coli* isolates in Iran. *J. Infect. Dev. Ctries.*, 2014; 8(7): 818-822.
30. Fursova Nadezhda K., Eugeny I. Astashkin, Anastasia I. Knyazeva, Nikolay N. Kartsev, Ekaterina S. Leonova, Olga N. Ershova, Irina A. Alexandrova, Natalia V. Kurdyumova, Svetlana Yu. Sazikina Edward A. Svetoch and Ivan A. Dyatlov. The spread of blaOXA-48 and blaOXA-244 carbapenemase genes among *Klebsiella pneumoniae*, *Proteus mirabilis* and *Enterobacter* spp. isolated in Moscow, Russia. *Ann Clin Microbiol Antimicrob*, 2015; 14(46): 2-9.
31. García-Fernández S, Morosini M-I, Gijón D, Beatobe L, Ruiz-Garbajosa P, Domínguez L, Cantón R, Valverde A. 2016. Detection of carbapenemase production in a collection of Enterobacteriaceae with characterized resistance mechanisms from clinical and environmental origins by use of both Carba NP and Blue-Carba tests. *J Clin Microbiol*, 54: 464-466.
32. Goni-Urriza, M., Capdepuy, M., Arpin, C., Raymond, N., Caumette, P., Quentin, C., Impact of an urban effluent on antibiotic resistance of riverine Enterobacteriaceae and *Aeromonas* spp. *Appl. Environ. Microbiol*, 2000; 66, 125-132.
33. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, et al. Emerging resistance to carbapenems in a tertiary care hospital in north India. *Indian J Med Res.*, 2006; 124(1): 95-98.
34. Gupta M, Gupta OK, Vanshi RKY, Upadhyaya J Burn epidemiology: the Pink City scene. *Burns*, 1993; 19: 47-51.
35. Hussein Nadheema Hammood, Harith Jabbar Fahad Al-Mathkhury and Majeed Arsheed Sabbah Imipenem-Resistant *Acinetobacter baumannii* isolated from patients and hospitals environment in Baghdad Iraqi *Journal of Science*, 2013; 54(4): 803-812.

36. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. *J Antimicrob Chemother*, 2008; 62: 895–904.
37. Knox J, Jadhav S, Seviour D, et al. Phenotypic Detection of Carbapenemase-Producing Enterobacteriaceae by Use of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and the Carba NP Test. *J Clin Microbiol*, 2014; 52: 4075–7.
38. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA - disk synergy tests to screen metallo- $\beta$ -lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin Microbiol Infect.*, 2001; 7: 88-91.
39. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge Test and the Imipenem-EDTA Double-Disk Synergy Test for Differentiating Metallo- $\beta$ -Lactamase Producing Isolates of *Pseudo- monas* spp And *Acinetobacter* spp. *J Clin Microbiol*, 2003; 41: 4623-4626.
40. Leepethacharat, K. and Oberdorfer, P. *Acinetobacter baumannii* Infection and Colonization among Pediatric Patients at Chiang Mai University Hospital. *J. Infect. Dis. Antimicrob. Agents*, 2007; 24(2): 63-73.
41. Manoharan A, Premalatha K, Chatterjee S, Mathai D, SARI Study Group Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamase among Enterobacteriaceae within their in vitro antimicrobial susceptibility. *Indian J Med Microbiol*, 2011; 29(2): 161-164.
42. Mathur, P.; Tatman, A.; Das, B. and Dhawan, B. Prevalence of extended beta lactamase producing Gram negative bacteria in a tertiary care hospital. *Indian J. Med. Res.*, 2002; 115: 153-157.
43. McWilliams Carla S, Susan Condon, Rebecca M. Schwartz, Christine C. Ginocchio. Incidence of Extended-Spectrum-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates That Test Susceptible to Cephalosporins and Aztreonam by the Revised CLSI Breakpoints *Journal of Clinical Microbiology*, 2014; 52(7): 2653–26.
44. Nigo M, Cevallos CS, Woods K, et al. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*, 2013; 57: 5743–5746.
45. Nordmann P, Dortet L, Poirel L. Rapid detection of extended-spectrum-beta-lactamase-producing Enterobacteriaceae. *J. Clin. Microbiol*, 2012a; Sep; 50(9): 3016-3022.
46. Nordmann P, Girlich D, Poirel L. Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium. *J Clin Microbiol*, 2012b; 50: 2761–2766.
47. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis.*, 2011a; 17: 1791-8.
48. Özdemir, H. ; Kendirli, T.; Ergün, H.; Çiftçi, E.; Tapısız, A.; Güriz, H.; Aysev, D.; İncel, E. and Doğru, Ü. Nosocomial infections due to *Acinetobacter baumannii* in a pediatric intensive care unit in Turkey. *The Turkish Journal of Pediatrics*, 2011; 53: 255-260.
49. Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis.*, 2008; 8: 159– 66.
50. Poirel, L.; Fortineau, N.; Nordmann, P. International transfer of NDM-1-producing *Klebsiella pneumoniae* from Iraq to France. *Antimicrob Agents Chemother*, 2011; 55: 1821-1822.
51. Prakash V, Lewis JS, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. *Antimicrob Agents Chemother*, 2009; 53: 1278–1280.
52. Roberts MC. Update on acquired tetracycline resistance genes. *FEMS Microbiology and Letters*, 2005; 245: 195–203.
53. Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). *Diagn Microbiol Infect Dis.*, 2013; 76: 217–221.
54. Shah Kinal Gaurishanker Shrimali, Summaiya Mulla. Comparison Of Double Disc Diffusion Method And Vitek 2 Compact System To Screen The Esbl Producers Inintensive Care Unit In Hospital *National Journal of Community Medicine*, 2016; 7(9): 789-791.
55. Shaikh, S. Fatima, J. and Kamal, M. A. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J. Biol. Sci.*, 2015; 22(1): 90-91.
56. Simner PJ, Gilmour MW, DeGagne P, Nichol K, Karlowsky JA. Evaluation of five chromogenic agar media and the Rosco Rapid Carb screen kit for detection and confirmation of carbapenemase production in Gram-negative bacilli. *J Clin Microbiol*, 2015; 53: 105–112.
57. Tran, J. H.; Jacoby, G. A. and Hooper, D.C. Interaction of the plasmid encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob. Agents Chemother*, 2005; 49: 118-125.
58. Vasoo S, Cunningham SA, Kohner PC, Simner PJ, Mandrekar JN, Lolans K, Hayden MK, Patel R. Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing gram-negative bacilli. *J Clin Microbiol*, 2013; 51: 3097–3101.

59. Vrioni, G., Daniil, I., et al., Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. *J. Clin. Microbiol*, 2012; 50(6): 1841–1846.
60. Wattal C, Goel N, Oberoi JK, Raveendran R, Dutta S, et al. Surveillance of multidrug resistant organisms in a tertiary care hospital in Delhi, India. *J Assoc Physicians India*, 2010; 58(1): 32-36.
61. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo- $\beta$ -lactamase-producing clinical isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol*, 2002; 40: 3798- 801.